The closing price of Caribou Biosciences Inc (NASDAQ: CRBU) was $7.22 for the day, down -2.70% from the previous closing price of $7.42. In other words, the price has decreased by -$0.20 from its previous closing price. On the day, 992066 shares were traded. CRBU stock price reached its highest trading level at $7.61 during the session, while it also had its lowest trading level at $7.18.
Ratios:
Our analysis of CRBU’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 14.27 and its Current Ratio is at 14.27. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.07.
On October 31, 2023, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $13.
On July 11, 2023, Truist started tracking the stock assigning a Buy rating and target price of $23.Truist initiated its Buy rating on July 11, 2023, with a $23 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRBU now has a Market Capitalization of 656.16M and an Enterprise Value of 345.13M. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.45 while its Price-to-Book (P/B) ratio in mrq is 1.60. Its current Enterprise Value per Revenue stands at 9.97 whereas that against EBITDA is -3.26.
Stock Price History:
Over the past 52 weeks, CRBU has reached a high of $8.59, while it has fallen to a 52-week low of $3.44. The 50-Day Moving Average of the stock is 6.38, while the 200-Day Moving Average is calculated to be 5.62.
Shares Statistics:
CRBU traded an average of 1.56M shares per day over the past three months and 1.29M shares per day over the past ten days. A total of 88.43M shares are outstanding, with a floating share count of 77.73M. Insiders hold about 12.10% of the company’s shares, while institutions hold 79.63% stake in the company. Shares short for CRBU as of Feb 15, 2024 were 9.69M with a Short Ratio of 6.21, compared to 9.86M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 10.96% and a Short% of Float of 11.50%.
Earnings Estimates
The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.37 for the current quarter, with a high estimate of -$0.21 and a low estimate of -$0.44, while EPS last year was -$0.44. The consensus estimate for the next quarter is -$0.41, with high estimates of -$0.34 and low estimates of -$0.45.
Analysts are recommending an EPS of between -$1.17 and -$1.46 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.74, with 8 analysts recommending between -$1.6 and -$1.87.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 6 analysts. It ranges from a high estimate of $9.1M to a low estimate of $2M. As of the current estimate, Caribou Biosciences Inc’s year-ago sales were $3.69M, an estimated increase of 24.90% from the year-ago figure.
A total of 8 analysts have provided revenue estimates for CRBU’s current fiscal year. The highest revenue estimate was $40M, while the lowest revenue estimate was $30.92M, resulting in an average revenue estimate of $34.89M. In the same quarter a year ago, actual revenue was $13.85M, up 151.90% from the average estimate.
